Compare TCI & MNPR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | TCI | MNPR |
|---|---|---|
| Founded | 1983 | 2014 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Real Estate | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 455.6M | 421.0M |
| IPO Year | N/A | 2019 |
| Metric | TCI | MNPR |
|---|---|---|
| Price | $52.73 | $70.29 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 13 |
| Target Price | N/A | ★ $101.42 |
| AVG Volume (30 Days) | 2.2K | ★ 365.1K |
| Earning Date | 11-06-2025 | 11-13-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 75.87 | N/A |
| EPS | ★ 0.65 | N/A |
| Revenue | ★ $48,675,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $81.12 | ★ N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $25.50 | $26.06 |
| 52 Week High | $59.65 | $105.00 |
| Indicator | TCI | MNPR |
|---|---|---|
| Relative Strength Index (RSI) | 50.59 | 49.99 |
| Support Level | $49.91 | $67.33 |
| Resistance Level | $53.94 | $76.13 |
| Average True Range (ATR) | 1.72 | 5.37 |
| MACD | -0.45 | 1.07 |
| Stochastic Oscillator | 34.95 | 67.10 |
Transcontinental Realty Investors Inc is a fully integrated externally managed real estate company. It operates multifamily and commercial properties throughout the southern United States and also invests in mortgage notes receivable and in the land that is either held for appreciation or development. The company has two business segments: the acquisition, development, ownership, and management of multifamily properties which include the rental of apartments (Residential Segment) and other tenant services, including parking and storage space rental, and the acquisition, development, ownership, and management of commercial properties which are office properties(Commercial Segment). It includes the rental of office space and other tenant services, including parking and storage space rental.
Monopar Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing proprietary therapeutics designed to extend life or improve the quality of life for cancer patients. The company's pipeline consists of Validive for the prevention of chemoradiotherapy-induced severe oral mucositis in oropharyngeal cancer patients, camsirubicinfor the treatmentof soft tissue sarcoma, a late-stage preclinical antibody, MNPR-101, for cancers and severe COVID-19 and an early-stage camsirubicin analog, MNPR-202, for various cancers.